undamentalytics Newsletter
Sign in

Stoke Therapeutics, Inc. revenue

Stoke Therapeutics, Inc.'s revenue was $184m in fiscal 2025, up 404.5% on the year before. Since fiscal 2022 ($12.4m) it has grown at a compound 145.9% a year. Over the last twelve months it was $27.6m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1293718428
Growth on the year before—−29.2%+316.3%+404.5%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Stoke Therapeutics, Inc. $27.6m -86.2% 46.1%
Monte Rosa Therapeutics, Inc. $28.7m -83.9% —
Tonix Pharmaceuticals Holding Corp. $29.1m 196.0% —
Arcturus Therapeutics Holdings Inc. $29.4m -76.0% -51.9%
Abeona Therapeutics Inc. $25.5m -87.7% 212.0%
Crispr Therapeutics AG $25.2m -34.3% -47.1%

Compare with peers

Head to head: GLUE vs STOKSTOK vs TNXPARCT vs STOKABEO vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Stoke Therapeutics, Inc.